Researchers postulated that brain insulin responsiveness may adapt to dietary changes before weight gain, potentially facilitating the development of obesity.
Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3
The US Food and Drug Administration (FDA) has approved suzetrigine 50 mg tablets, a first-in-class nonopioid analgesic for treatment of adults with moderate-to-severe acute pain.
As the use of glucagon-like peptide 1 receptor agonists continues to exponentially expand obesity treatment, concerns have arisen regarding their impact on nutrition in people who take them